Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COMPASS Pathways Plc CMPS

Healthcare Biotechnology
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.


NDAQ:CMPS - Post by User

COMPASS Pathways Plc
Bullboard Posts
User Avatar Image
(0)
•••
Post by Nonyahon Oct 13, 2020 12:13pm
105 Views
Post# 31707335

Compass Pathways (NASDAQ: CMPS), made headlines across mains

Compass Pathways (NASDAQ: CMPS), made headlines across mains

9. Headaches, Bad Trips, Flashbacks, Psychosis: Addressing the Dark Side of Psychedelics

Treatments Using Psychedelics Have Gained Momentum Over the Last Year, as More Companies Are Courting Investor Interest

One of those companies, Compass Pathways (NASDAQ: CMPS), made headlines across mainstream media recently as the first Psychedelic medicine company to be listed on a major U.S. stock exchange, the NASDAQ........

https://www.thecannabisinvestor.ca/cannabis-countdown-top-10-marijuana-and-psychedelic-stock-news-stories-of-the-week-31/

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities